Introduction {#S5}
============

Infants born at the limits of viability are susceptible to morbidities involving many organ systems. Retinopathy of prematurity (ROP) is a well-known morbidity specific to the developing eye. This disease involves the abnormal maturation of the retinal vasculature, and it is one of the most common causes of irreversible childhood blindness today ([@R1]). Although epidemiological evidence indicates ROP to be associated with multiple risk factors such as prematurity, oxygen use, low birth weight, infections, and poor postnatal weight gain, the etiopathogenesis of this disorder remains unclear ([@R1]-[@R5]).

Vascular endothelial growth factor (VEGF), a well-characterized regulator of angiogenesis, has been mechanistically implicated in retinal neovascularization and in the pathogenesis of ROP ([@R6]-[@R9]). Understanding the ontogeny of VEGF expression in the normal human fetal retina is an important step in the study of angiogenic factors operative in ROP ([@R10], [@R11]). In this study, we hypothesized that VEGF expression increases in the midgestation human fetal eye as a function of gestational age, and measured VEGF isoforms and splice variants in retinal tissue and vitreous fluid obtained from fetuses of 10-24 weeks gestation.

Results {#S6}
=======

Endogenous controls {#S7}
-------------------

We evaluated beta-actin (β-actin), glyceraldehyde 3-phosphate dehydrogenase (GAPDH), hypoxia inducible factor 1 alpha (HIF-1α) and ribosomal 18s as possible genes to serve as normalizing controls in quantitative PCR (qPCR) reactions ([figure 1](#F1){ref-type="fig"}). We found no statistical difference in gene expression across all gestational ages tested (10-24 weeks) with GAPDH (p=0.108), β-actin (p=0.522) or HIF-1α (p=0.077), while 18s gene expression increased significantly from early to late mid-gestation with 18s (p=0.006). We chose GAPDH to serve as our endogenous control because of its relative abundance in relation to VEGF.

VEGF concentrations in serum and vitreous {#S8}
-----------------------------------------

We initially measured VEGF concentrations in vitreous and serum in 10-24 week fetal samples ([figure 2](#F2){ref-type="fig"}). The ELISA primarily measured VEGF~165~ but could not distinguish VEGF~165~ from VEGF~121~. Serum VEGF~165/121~ concentrations were significantly higher at 10-14 weeks gestation than concentrations at other gestational ages, and were higher than vitreous concentrations at 10-14 weeks (p\<0.05). Vitreous VEGF~165/121~ concentrations were similar among gestational age groups, and were similar to serum concentrations at 15-17, 18-21, and 22-24 weeks gestation.

VEGF-A expression increases in the 2^nd^ trimester retina with advancing gestation {#S9}
----------------------------------------------------------------------------------

We measured mRNA expression of VEGF-A, -B, -C, and -D isoforms in fetal retinal tissue by RT-qPCR. As shown in [figure 3](#F3){ref-type="fig"}, the expression of VEGF-A, but not VEGF-B, -C, or D, increased in the midgestation retina as a function of gestation age. VEGF mRNA expression showed a strong positive correlation with gestational age (*inset*; Spearman\'s r = 0.77, *p*\<0.05). Consistent with these findings, we measured VEGF in retinal tissue and showed higher VEGF-A protein expression in tissue from 20-24 week fetuses than 11-14 week fetuses ([figure 4](#F4){ref-type="fig"}).

VEGF~121~ is the predominant splice variant of VEGF-A in the midgestation fetal retina {#S10}
--------------------------------------------------------------------------------------

We next PCR-amplified major splice variants of VEGF-A mRNA in retinal tissue from fetuses of 20-24 weeks\' gestation. As shown in [figure 5](#F5){ref-type="fig"}, VEGF~121~was the predominant splice variant of VEGF-A, but we also detected faint bands of VEGF~165~ and VEGF~189~. These findings were specific to the retina; we detected only VEGF~121~and VEGF~206~ in the fetal brain, but all the 5 splice variants in the fetal colon at the same gestational age.

We next used our SYBR green I-based qPCR protocol to measure the developmental changes in VEGF~121~, VEGF~165~, and VEGF~189~. Although all the three splice variants showed increased expression with advancing gestation, VEGF~121~ and VEGF^165^ showed a greater developmental change than VEGF^189^ ([figure 6](#F6){ref-type="fig"}).

VEGF concentrations increase in the vitreous humor with advancing gestation {#S11}
---------------------------------------------------------------------------

Existing information indicates that VEGF~121~ and VEGF~165~ are diffusible proteins, in contrast to the larger, tissue-bound VEGF~189~ protein ([@R12]). Therefore, to confirm the biological relevance of our findings at the protein level, we next measured VEGF~121~concentrations in vitreous humor from these fetuses. As shown in [figure 7](#F7){ref-type="fig"}, VEGF~121~ concentrations increased in vitreous humor with advancing gestation. Compared to fetuses of 10-14 weeks\' gestation, there was a trend towards higher vitreous VEGF~121~ concentrations at 15-19 weeks, and significantly higher VEGF~121~ concentrations at 20-24 weeks.

Discussion {#S12}
==========

The normal role of VEGF in the developing human eye continues to be evaluated. In this study we found increasing concentrations of retinal VEGF-A mRNA with increasing gestational age in the human fetal eye. VEGF~121~ was the predominant splice variant of VEGF-A in fetal retina, and consistent with these findings, we detected increasing VEGF~121~ concentrations in vitreous humor with increasing gestational age. Our findings of increasing retinal VEGF mRNA and total VEGF protein with increasing gestational age are consistent with the developing vasculature of the eye.

Vascularization in the eye begins during the fifth week of gestation and is not completed until after birth ([@R2], [@R8]). The eye has an initial vascular system that develops but then regresses when the permanent retinal vascular system, limited to the inner two-thirds of the retina, starts to develop in the fourth month of gestation ([@R8]). Due to its tissue origins, the retina is thought to be primarily vascularized by angiogenesis, the formation of vessels from existing vessels, rather than vasculogenesis, the *de novo* formation of vessels ([@R8], [@R10]). VEGF is the primary hypoxically-regulated growth factor responsible for angiogenesis, which includes formation of the hyaloid vascular system early in development as well as later retinal vessel formation. However, before it assumes its role as a angiogenic factor, VEGF may also serve as a neurogenic factor for progenitors and newly postmitotic cells in the prevascular retina ([@R13]).

The term VEGF is often used synonymously with its isoform A. The gene is organized in 8 exons ([@R6], [@R14], [@R15]), where differential splicing results in two families of isoforms, one that is pro-angiogenic involved in neovascularization and the other that is anti-angiogenic inhibiting blood vessel proliferation ([@R16]). The isoforms formed from alternative splicing of the VEGF-A gene that are present in both families, include at least 4 transcripts containing 121, 165, 189, and 206 amino acid residues. These VEGF-A isoforms have functionally unique, biological activity and are distinguished by their affinity for heparin ([@R9], [@R14], [@R17]). VEGF-A has also been shown to be necessary for the development and stability of retinal vessels ([@R18]). The smaller isoforms, 121 and 165, are diffusible proteins; whereas, the larger isoforms, 189 and 206, have a high affinity for heparin and are bound to tissue. We detected VEGF~121~ to be the predominant splice variant of VEGF-A in the fetal retina. These findings show an interesting contrast with the adult retina, where the predominant splice variant is VEGF~165~ ([@R19]). Further study is needed to determine whether this developmental dichotomy in VEGF-A splice variants remains true in ROP and other retinal disorders.

The mechanisms for the observed maturational increase in VEGF expression in the developing retina are unclear. However, existing data indicate a role for several growth factors and cytokines as regulators of VEGF-A expression and splicing ([@R20]). For instance, transforming growth factor-beta (TGF-β) has been shown to act via the p38 MAPK to activate SR protein splicing factors such as SRp55, which binds the VEGF pre-RNA in the exon 8b region ([@R21]). Similarly, insulin-like growth factor (IGF)-1 can phosphorylate ASF/SF2 (alternative splicing factor/splicing factor 2) through the SR protein kinase SRPK1 (serine/arginine domain protein kinase 1) ([@R22]). ASF/SF2 can bind to VEGF pre-RNA around proximal splice-site selection) and results in differential expression of various splice variants of VEGF-A. IGF-1 may also regulate VEGF expression via hypoxia-induced factor (HIF)-1α -dependent and -independent pathways. HIF-1α is known to be abundant in hypoxic tissues with active angiogenesis ([@R22]). While HIF 1 expression did not significantly increase with development, there was a trend. This fits with our understanding of the role of "physiological hypoxia" in retinal vessel development.

Previous studies have evaluated the concentration of VEGF protein in the eye. Gogat and colleagues ([@R8]) determined the distribution of VEGF on retinal sections during development and noted that VEGF transcripts had a temporal and spatial correlation with normal development of human ocular vasculature. That study did not detect VEGF mRNA in older mid-gestational tissues, but did detect VEGF protein. In another study, Kim *et al.* ([@R23]) evaluated the levels of VEGF mRNA transcripts and protein in samples from normal monkeys, and detected constitutive expression of VEGF, VEGFR-1, and VEGFR-2. Pierce *et al.* ([@R24]) showed that VEGF mRNA levels, followed by VEGF protein, increase in a mouse model with relative retinal hypoxia. In another study, Pe\'er *et al.* ([@R25]) showed that abnormal retinal vessel growth in human and rabbit neovascular retinas was associated with dramatic elevations of retinal VEGF expression compared to control retinas. These findings are consistent with our hypothesis that VEGF has an integral role in the normal development of the human eye, and abnormal levels may be associated with ROP.

Our findings provide important physiological information on the normal expression of VEGF in the developing retina. Although the pathophysiology of ROP is not well- understood because of the complexity of this disease, the role of VEGF is now widely-accepted ([@R10], [@R26], [@R27]). ROP has a well-recognized progression in the retina that is divided into two discrete, but associated, stages: cessation of normal retinal angiogenesis and a subsequent hyperproliferative neovascular response to retinal ischemia where the 1^st^ phase occurs from 22 to 30 weeks postmenstrual age, and phase 2 from 31 to 44 weeks\' postmenstrual age ([@R2], [@R28], [@R29]). Phase 1 occurs when the premature infant is exposed to relative hyperoxia, often associated with supplemental oxygen, resulting in reduced VEGF expression. Understanding these relationships between oxygen and VEGF can help improve the management of ROP, including both the prevention as well as early (i.e., in phase 1) and later treatment (i.e., in phase 2) ([@R30]). The role of growth factors, including erythropoietin ([@R31], [@R32]), IGF-1 ([@R2]), and matrix metalloproteinases ([@R33]), on VEGF expression in the normal retina and in ROP needs further evaluation. The efficacy of anti-VEGF agents such as intravitreal bevacizumab in ROP has also emphasized the important pathophysiological role of VEGF in ROP ([@R34]). Identification of the specific isoforms of VEGF expressed in the developing retina could help reduce adverse effects and facilitate the development of more specific anti-VEGF agents. In the adult retina, the anti-angiogenic VEGF~165~ antibody inhibits hypoxia-induced neovascularization ([@R16]), although our findings indicate a need to confirm whether VEGF~121~ or VEGF~165~ is the predominant splice variant of VEGF-A in ROP.

Methods {#S13}
=======

Fetal tissues {#S14}
-------------

This study was evaluated by the Human Research Review Committee at the University of New Mexico and deemed not to constitute human subject research as no identifiable human subject data were collected. Vitreous, serum, and retinal tissue samples were collected from fetuses between 10 and 24 weeks gestation for measurement of VEGF mRNA and protein. The gestational age grouping was chosen based on availability of the tissue. Samples were divided into early, mid and late second trimester based on distribution across the 10-24 week gestation range. All biological specimens were handled and stored similarly accordingly to a standardized checklist. Gestational age was estimated based on fetal foot length. Gender could not be determined on most samples, and this information was not collected. The contents of the globe were extracted, retinal tissue (including choroid) isolated ([figure 8](#F8){ref-type="fig"}), and the aqueous and vitreous collected from both fetal eyes and combined for each sample. Vitreous samples were clarified by centrifugation at 200*g* × 5 min and then frozen until the time of analysis. Retinal tissue from both eyes was triturated using serially smaller syringes in a commercially-available lysis buffer (T-PER tissue protein extraction reagent with added protease inhibitors; Thermo Scientific, Rockford, IL) for measurement of total protein concentration by the Bradford assay (Thermo Scientific).

Western blots {#S15}
-------------

Tissue-bound VEGF-A protein was measured in retinal samples in Western blots using a mouse monoclonal IgG~1~ that detects the -189, -165 and -121 amino acid splice variants (Santa Cruz Biotech, Santa Cruz, CA) and established methods ([@R35]). This antibody detects VEGF as a dimer of 43 kDa molecular weight.

Reverse transcriptase-quantitative polymerase chain reaction (RT-qPCR) {#S16}
----------------------------------------------------------------------

Total RNA was extracted from fetal retinal samples using the single-step acid guanidinium thiocyanate-phenol-chloroform extraction ([@R36]) and was then reverse-transcribed using a commercially-available kit (cDNA Archive kit, Applied Biosystems, Foster City, CA). The expression of VEGF isoforms A-D was measured using standard SYBR green I-based RT-qPCR ([@R37]).

Isoform-specific primers were designed using the Beacon Design software (Bio-Rad, Hercules, CA): VEGF-A forward: CCTTGCCTTGCTGCTCTAC, reverse: TTCTGCCCTCCTCCTTCTG; VEGF-B forward: GGACAGAGTTGGAAGAGGAGAC, reverse: GGAAGAGCCAGTTGTAAGATGC; VEGF-C forward: CAGACAAGTTCATTCCATTATTAG, reverse: AGTCATCTCCAGCATCCG; VEGF-D forward: TCCAGACCAACCTTCCATTCAC, reverse: CAGCACACCTTTCTCATTCACC. For quantitative measurements, we developed a standard curve by reverse-transcribing serial dilutions of total RNA from Hep3B cells, an immortalized cell line that constitutively expresses VEGF ([@R38]).

The architecture of VEGF-A was analyzed using the databases aceview ([@R19]), GeneCard ([@R39]), and Ensembl ([@R29]), and splice variant-specific amplicons were identified as previously described by Lamani *et al.* ([@R40]). We used forward primers designed specifically for each splice variant: VEGF~121~: GAGCAAGACAAGAAAAATGTG; VEGF~165~: CAGACTCGCGTTGCAAGATG; VEGF-183: GTATAAGTCCTGGAGCGTTCC; VEGF~189~: AAGCGCAAGAAATCCCGTCC; and VEGF~206~: TGCTGTCTAATGCCCTGGAG, and combined these with a common reverse primer: GTCTTCACTGGATGTATTTGAC. PCR products were resolved in agarose gels for qualitative analysis. In some experiments, fetal brain and colonic tissue were included for control.

VEGF~121~ enzyme-linked immunosorbent assay (ELISA) {#S17}
---------------------------------------------------

VEGF protein concentrations were initially quantified by ELISA that had a linear range of 15.6-1000 pg/mL (R&D Systems, Minneapolis, MN). The commercially available kit was designed to measure VEGF~165~, but per manufacturers information could not distinguish VEGF~165~ from VEGF~121~. Additional analyses were therefore performed on available vitreous samples. VEGF~121~ was measured in vitreous humor using an ELISA kit that includes a capture antibody specific for VEGF~121~ and does not display cross-reactivity for other splice variants of VEGF (MyBiosource, San Diego, CA). This assay had a linear range of 15.625-1000 pg/mL. Samples containing VEGF concentrations greater than the upper limit of the assay were re-tested in dilution. Data were normalized against the total protein concentration in each vitreous sample.

Statistical methods {#S18}
-------------------

Parametric and non-parametric tests were applied using the the Sigma Stat 3.1.1 software (Systat, Point Richmond, CA). Regression analyses and ANOVA were performed on endogenous control data. For PCR data, crossing-threshold (ΔΔCT) values were compared across experimental groups using analysis of variance or the Kruskal-Wallis *H* test/Dunn\'s multiple post-test. In all tests, *p*\<0.05 was accepted as significant.
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![Gene expression of GAPDH, β-actin, 18s and HIF-1α\
Gene expression in retina for GAPDH (panel A), 18s (panel B) β-actin (panel C), and HIF-1α (panel D) from 10-24 week samples is shown. Gene expression of GAPDH, β-actin and HIF-1a was not significantly different across the range of gestational age tested, while gene expression of 18s increased with increasing gestational age (p=0.006).](nihms640506f1){#F1}

![VEGF protein concentrations in fetal serum and vitreous\
VEGF~165/121~ protein concentrations in serum (black bars) and vitreous (grey bars) measured from 10 to 24 weeks gestation. VEGF~165/121~ protein concentrations were significantly greater in serum at 10-14 weeks (p\<0.05) than in serum at other gestational ages, while concentrations in vitreous were similar at all gestational ages tested. Serum VEGF~165/121~ protein concentrations were similar to vitreous concentrations from 15-24 weeks.](nihms640506f2){#F2}

![VEGF-A mRNA expression in the 2^nd^ trimester retina with advancing gestation\
Bar diagrams (means ± SE) show fold change in the mRNA expression of VEGF isoforms, VEGF-A, -B, -C, and -D, in retinal tissue from fetuses of 10-14 weeks, 15-19 weeks, and 20-24 weeks gestation. *Inset:* Scatter-plot of relative RNA expression of VEGF/18S ribosomal RNA *vs.* gestational age. R = Spearman\'s correlation coefficient). \* indicates *P*\<0.05.](nihms640506f3){#F3}

![Tissue-bound VEGF-A protein expression in retinal tissue from fetuses at 10-14 weeks and 20-24 weeks gestation\
Representative Western blots show tissue-bound VEGF-A and β-actin. Bar-diagrams (means ± SE) summarize densitometric data.](nihms640506f4){#F4}

![VEGF-A splice variants in the midgestation fetal retina\
***Top:*** Schematic shows the complete pre-mRNA and the major splice variants of VEGF-A. The site of the primers is indicated by arrows. ***Bottom:*** Representative agarose gels showing PCR products corresponding to the major splice variants in fetal retina, brain, and colon.](nihms640506f5){#F5}

![Developmental change in VEGF-A splice variants in the midgestation fetal retina\
Bar diagrams (means ± SE) show fold change in the mRNA expression of VEGF-A splice variants, VEGF~121~, VEGF~165~, and VEGF~189~, in retinal tissue from fetuses of 10-14 weeks, 15-19 weeks, and 20-24 weeks. \* indicates *P*\<0.05.](nihms640506f6){#F6}

![VEGF~121~ concentrations increase in the vitreous humor with advancing gestation\
Box-plots show VEGF~121~ concentrations in vitreous humor from fetuses of 10-14 weeks, 15-19 weeks, and 20-24 weeks. \* indicates *P*\<0.05.](nihms640506f7){#F7}

![Fetal eyes and retina\
Fetal eyes at 14 weeks and 18 weeks gestation (panel A) are shown. Dissection of the 18 week fetal eye revealing the retina and choroid is shown (panel B).](nihms640506f8){#F8}
